NCT05666713Completed
NHLBI Transmural Electrosurgery LeafLet Traversal And Laceration Evaluation (TELLTALE) BASILICA-TAVR Trial
Source: ClinicalTrials.gov · Last updated 3 Feb 2026
Brief summary (registry, in English)
Background: Replacing a valve in the heart can save many people's lives. The procedure is called transcatheter aortic valve replacement (TAVR). In rare cases, a flap of tissue called a leaflet can shift during TAVR; the leaflet may block blood flow to the coronary arteries, which supply blood to the heart muscle. About 50% of people who experience this problem will die. To reduce this risk, doctors will cut this leaflet during TAVR. But the tools used to cut the leaflet were originally designed for other purposes. Using these tools during TAVR can be complicated and risky. Researchers want to make TAVR safer. Objective: To test a new device (TELLTALE) designed specifically for use during TAVR. Eligibility: People aged 21 years and older who are undergoing TAVR and who are at high risk of coronary artery obstruction. Design: Participants will be screened. They will have routine tests that are done before undergoing TAVR. Before the procedure, participants will complete a questionnaire. They will talk about how their heart disease affects their quality of life. Their physical abilities and their risk of stroke will be assessed. Participants will be admitted to the hospital for TAVR. They will be placed under general anesthesia or moderate sedation. The procedure will be performed using the TELLTALE guidewire system. Participants will repeat the tests of their physical abilities after the procedure. They will also repeat the questionnaire about their quality of life. These will be repeated again at a follow-up visit in 30 days. Participants will have a final study visit after 90 days. This visit may be in person or remote.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 90 (actual)
- First submitted
- 24 Dec 2022
- Start date
- 21 Feb 2023
- Primary completion date
- 14 Feb 2025
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NCT number
- NCT05666713
What you commit to
- Study type: Interventional
- Participants enrolled: 90
- From 21 Feb 2023 to the primary completion date, 14 Feb 2025
- 10 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Requires concomitant procedures during TAVR (such as percutaneous coronary intervention for baseline obstructive coronary artery disease)
Lab values
- Excessive target aortic leaflet calcification (no basal calcium-free window or potentially obstructive calcific masses) on baseline CT
- Chronic kidney disease KDIGO stage 4 or 5 (eGFR \< 29 ml/min/1.73m2) or renal replacement therapy
Other
- Requires doppio (two-leaflet) BASILICA
- Flail target leaflet at baseline
- Planned provisional (pre-position coronary artery) stents despite BASILICA
- Requires non-femoral access
- Not expected to survive for 12 months
- Pregnant at the time of intended treatment (day 0)
Criteria the registry did not label
- INCLUSION CRITERIA:
- In order to be eligible to participate in the study, candidates must meet all of the following criteria:
- Adults age \>= 21 years
- High or prohibitive risk of surgical aortic valve replacement according to the local multidisciplinary heart team
- Undergoing TAVR for bioprosthetic aortic valve failure or native aortic stenosis ( on-label TAVR)
- Local multidisciplinary heart team determines subject to be at high risk of TAVR-induced coronary artery obstruction
- Deemed likely to suffer coronary artery obstruction from TAVR based on NHLBI Core lab analysis of CT, any of
- Risk is narrow Sinus of Valsalva: (a) Leaflet height is greater than coronary artery height, and (b) Virtual transcatheter valve-to-coronary (VTC) distance \< 4mm
- Risk is Sinus sequestration: (a) Threatening leaflet height is greater than sinotubular junction, and (b) Virtual transcatheter valve-to-sinotubular-junction distance (VTS) \< 2mm at the affected Sinus
- Concurrence of the Study Eligibility Committee
- Able to understand the protocol, consents in writing to participate, and willing to comply with all study procedures for the duration of the study
Age in the registry: 21 years to 109 years · Sex: All · Does not accept healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Emory University Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| Beth Israel Deaconess Medical Center Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| University of Colorado Health Coordinator of this site? Confirm its status | Fort Collins | United States | Unknown status |
| Carilion Medical Center Coordinator of this site? Confirm its status | Roanoke | United States | Unknown status |
| Rochester Regional Health Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
| St. Francis Hospital and Heart Center Coordinator of this site? Confirm its status | Roslyn | United States | Unknown status |
| California Pacific Med Ctr Coordinator of this site? Confirm its status | San Francisco | United States | Unknown status |
| University of Washington Heart Institute Coordinator of this site? Confirm its status | Seattle | United States | Unknown status |
| Montefiore Medical Center Coordinator of this site? Confirm its status | The Bronx | United States | Unknown status |
| Medstar WHC Coordinator of this site? Confirm its status | Washington D.C. | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.